A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study

Trial Profile

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Carotuximab (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms AVANTE Study
  • Sponsors Santen Pharmaceutical
  • Most Recent Events

    • 06 Jul 2017 Status changed from planning to recruiting.
    • 10 May 2017 According to a TRACON Pharmaceuticals media release, dosing will start in the second half of 2017.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top